Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 2/20 | 0.59 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | IDE | P14735 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3531018 | 0.81 | PANK3 (0.49) | PANK3MAPTMEN1KMT2APOLB | |
| SCHEMBL3558471 | 0.81 | MAPT (0.51) | KITIDEHRH1SLC6A15MAPT | |
| SCHEMBL3531390 | 0.81 | TRPV1 (0.53) | KITIDEHRH1SLC6A15SMO | |
| SCHEMBL12991321 | 0.80 | MAPT (0.46) | ACHEMAPTMEN1KMT2APTPN11 | |
| SCHEMBL30166226 | 0.79 | ACHE (0.61) | PANK3ACHEMAPTMEN1KMT2A | |
| SCHEMBL1433109 | 0.79 | ACHE (0.61) | PANK3ACHEMAPTMEN1KMT2A | |
| SCHEMBL20425052 | 0.78 | PANK3 (0.60) | PANK3ACHEMEN1KMT2ASMO | |
| SCHEMBL3528119 | 0.77 | FAAH (0.42) | ACHEMAPTMEN1KMT2APTPN11 | |
| SCHEMBL11160876 | 0.77 | MEN1 (0.52) | KITMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL3804468 | 0.77 | KIT (0.45) | KITIDEHRH1SLC6A15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858786-B2 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCOROPATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858786-B2 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCOROPATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858786-B2 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCOROPATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7705002-B2 | Biaryls useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080090837-A1 | Na channel and Ca channel antagonists; potentiation; side effects reduction; pains, epilepsy, neurodegenerative disorders, psychiatric disorders,movement disorders, neuroendocrine disorders etc.; 2-hydroxy-1-[4-[3-(2-hydroxyphenyl)phenyl]piperazin-1-yl]-4-methyl-pentan-1-one; | VERTEX PHARMACEUTICALS INCORPORATED | 2008-04-17 | — | — | US | disclosed |
| EP-1888549-A2 | BIARYLS USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1877385-A1 | PYRIMIDINES AND PYRAZINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-26 | — | — | US | disclosed |
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-26 | — | — | US | disclosed |
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-26 | — | — | US | disclosed |
| WO-2006124865-A2 | BIARYLS DERIVATIVES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006119451-A1 | PYRIMIDINES AND PYRAZINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090837-A1 | Na channel and Ca channel antagonists; potentiation; side effects reduction; pains, epilepsy, neurodegenerative disorders, psychiatric disorders,movement disorders, neuroendocrine disorders etc.; 2-hydroxy-1-[4-[3-(2-hydroxyphenyl)phenyl]piperazin-1-yl]-4-methyl-pentan-1-one; | CACNA1B, SCN1A, CACNA1S | PANK3 833/4885KIT 2795/4885IDE 3112/4885 |
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | KCNJ1, KCNJ2, KCNJ11 | PANK3 897/4885KIT 3315/4885IDE 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.